Travere Therapeutics, Inc. Provides Financial Guidance for the Fourth Quarter and for the Fiscal Year 2022
For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue.